SCHEDULE 13G/A: Forbion Entities Disclose 6.8% Passive Stake in Astria Therapeutics

ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. have jointly disclosed a passive beneficial ownership of 6.8% in Astria Therapeutics, Inc.'s common stock.

Summary

• ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The Reporting Persons collectively beneficially own 3,822,537 shares of Astria Therapeutics, Inc. Common Stock.
• This ownership represents approximately 6.8% of the outstanding shares of Astria Therapeutics, Inc.
• The percentage is calculated based on 56,434,219 shares of Common Stock outstanding as of February 28, 2025, as disclosed in Astria Therapeutics' Annual Report on Form 10-K filed on March 11, 2025.
• ForGrowth III directly owns the 3,822,537 shares.
• Forbion Growth III COOP, as the sole shareholder of ForGrowth III, and Forbion Growth III Management B.V., as director of both ForGrowth III and Forbion Growth III COOP, may be deemed to have shared voting and investment power over these shares.
• The Reporting Persons are organized under the laws of the Netherlands and their principal business office is in Naarden, The Netherlands.
• The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing the control of Astria Therapeutics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral, compliance-driven filing.

Risks

• The Reporting Persons disclaim membership in a 'group' for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, despite making a single, joint filing because they may be deemed to constitute a 'group'.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Astria Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.

Industry Context

This Schedule 13G filing indicates a significant passive investment by a Netherlands-based investment group, Forbion, in Astria Therapeutics, a U.S. biotechnology company. Such filings are common in the biotech sector, where specialized funds often take strategic stakes in companies developing novel therapies. Forbion's focus on growth opportunities suggests a long-term view on Astria's potential, aligning with broader trends of institutional investment in promising life sciences ventures.

Stakeholder Impact

• Shareholders: The disclosure of a significant 6.8% stake by a reputable investment group like Forbion could be viewed positively by existing shareholders, signaling institutional confidence in Astria Therapeutics. It also identifies a major shareholder whose interests may align with long-term value creation.

Key Dates

Keywords

Astria Therapeutics, Forbion, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Fund